Spinal cord stimulation for severe restless legs syndrome that has not responded to treatment
Tests an implanted spinal cord stimulator in adults with severe restless legs syndrome.
Key facts
- Who runs it
- Marshall Holland
- Where
- Birmingham, United StatesSee the site
- Trial code
- Registry title
- Neuromodulation to Overcome Severe Restless Legs Syndrome
- Status
- Not yet recruiting
- People taking part
- 15 people, planned
- Starts
- Oct 2027
- Expected to end
- Oct 2034
- Type of study
- Interventional
- Treatments tested
- Spinal Cord Stimulation
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe primary Restless Legs Syndrome (RLS) that has not improved enough with usual treatment. Participants get an implanted spinal cord stimulation device and are followed for 24 months.
- Age
- Over 18 years (minimum age 18 Years).
- Sex
- All sexes can join.
- Disease stage
- Severe RLS with an IRLS Scale score ≥ 21. Symptoms occur ≥ 3 nights per week. A sleep medicine doctor must find that standard RLS treatment did not work or did not work well enough.
- Earlier treatment
- Standard medical treatment for RLS must have failed or not helped enough. People who had a spinal cord stimulation trial or implant before cannot join.
- Biomarker or test result
- RLS diagnosis confirmed with the Cambridge Hopkins-RLS questionnaire and the Hopkins-Hening Diagnostic questionnaire. Ferritin must not be < 50 ng/mL. HgA1C must not be > 7.5.
Main reasons for not taking part
- An active medical implant, such as a pacemaker, or another device used to treat RLS.
- Nerve pain other than RLS, severe peripheral neuropathy, spinal cord injury or prior spine surgery.
- Pregnant, breastfeeding, or trying to become pregnant.
- Epilepsy, multiple sclerosis, Parkinson's disease or other severe movement disorder, deep vein thrombosis, or cancer within the past 5 years (except basal or squamous cell skin cancer).
- Drug or alcohol abuse within the past year, severe psychiatric or memory disorder, or an active or chronic infection.
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age >18 years and older
- Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire
- IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician
- RLS symptoms occur ≥ 3 nights per week
- Willing and able to comply with study procedures
- Able to provide informed consent
Who cannot take part
- Active medical implant in the body (i.e., pacemaker)
- History of prior SCS trial or implantation
- Currently using another device to treat RLS
- One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials
- Other medical conditions that would put the subject at risk as determined by the investigators
- HgA1C > 7.5 (excludes unstable diabetes melilitus)
- Age <18 years
- Neuropathic pain, other than RLS on DN4 questionnaire
- Any mental or physical limitation that would prevent completing and of the study protocols
- Unable or unwilling to comply with study protocols
- Pregnant, breastfeeding, or trying to become pregnant
- Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS
- Ferritin < 50 ng/mL (excludes iron deficiency)
Where in United States
- UAB HospitalBirmingham, United StatesContact: Chris GonzalezNot yet recruiting
About the trial
What the trial wants to find out
This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.
The group in the trial
- SCS ImplantTreatment being tested
Treatment: Spinal Cord Stimulation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
- Plain-language title
- Spinal cord stimulation for severe restless legs syndrome that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 October 2026